Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETY or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma.

Paris (France)


– First phase 3 trial in a global clinical development program to explore the combination of these agents –


– Exelixis, Bristol-Myers Squibb and Ipsen to co-fund this trial –